What is Qualtan?
Qualtan is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks.
Qualtan is also used to lower the risk of heart attacks or stroke in patients 55 years of age and older who have diabetes or heart problems.
Qualtan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, Qualtan relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart.
Qualtan is available only with your doctor's prescription.
Qualtan indications
Hypertension: Treatment of essential hypertension.
Cardiovascular Risk Reduction: Qualtan is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.
High risk of cardiovascular events can be evidenced by history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or high-risk diabetes (insulin-dependent or non-insulin dependent) with evidence of end-organ damage. Qualtan can be used in additional to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).
Studies of Qualtan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves.
Use of Qualtan with an ACE inhibitor is not recommended.
How should I use Qualtan?
Use Qualtan as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Qualtan. Talk to your pharmacist if you have questions about this information.
- Take Qualtan by mouth with or without food.
- Do not remove the tablet from the blister seal until you are ready to take your dose.
- Take Qualtan on a regular schedule to get the most benefit from it. Taking Qualtan at the same time each day will help you remember to take it.
- Continue to take Qualtan even if you feel well. Do not miss any doses.
- If you miss a dose of Qualtan, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Qualtan.
Uses of Qualtan in details
Qualtan belongs to a class of medicines known as angiotensin II receptor blockers. It is used to treat high blood pressure, prevention and treatment of heart attack (myocardial Infarction) and heart failure; when heart is unable to pump sufficient blood. It is also used for kidney failure in patients with diabetes.
Qualtan description
Qualtan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as Qualtan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that Qualtan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.
Qualtan dosage
Qualtan Dosage
Generic name: Qualtan 20mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
2.1 Hypertension
Dosage must be individualized. The usual starting dose of Qualtan tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg.
Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg Qualtan is required, a diuretic may be added.
No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension; their blood pressure should be closely monitored.
Qualtan tablets may be administered with other antihypertensive agents.
Qualtan tablets may be administered with or without food.
2.2 Cardiovascular Risk Reduction
The recommended dose of Qualtan tablets is 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of Qualtan are effective in reducing the risk of cardiovascular morbidity and mortality.
When initiating Qualtan therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.
More about Qualtan (Qualtan)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 25 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Qualtan
- Qualtan (Advanced Reading)
Professional resources
- Qualtan (AHFS Monograph)
- Qualtan (FDA)
Other formulations
- Qualtan HCT
Related treatment guides
- Cardiovascular Risk Reduction
- High Blood Pressure
- Prevention of Cardiovascular Disease
Qualtan interactions
See also:
What other drugs will affect Qualtan?
Aliskiren: Do not co-administer aliskiren with Qualtan in patients with diabetes. Avoid use of aliskiren with Qualtan in patients with renal impairment (GFR < 60 mL/min).
Digoxin: When Qualtan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing Qualtan for the purpose of keeping the digoxin level within the therapeutic range.
Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including Qualtan. Therefore, monitor serum lithium levels during concomitant use.
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Qualtan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Qualtan and NSAID therapy.
The antihypertensive effect of angiotensin II receptor antagonists, including Qualtan may be attenuated by NSAIDs including selective COX-2 inhibitors.
Ramipril and Ramiprilat: Co-administration of Qualtan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state Cmax and AUC of ramipril 2.3-and 2.1-fold, respectively, and Cmax and AUC of ramiprilat 2.4-and 1.5-fold, respectively. In contrast, Cmax and AUC of Qualtan decrease by 31% and 16%, respectively. When co-administering Qualtan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of Qualtan. Concomitant use of Qualtan and ramipril is not recommended.
Other Drugs: Co-administration of Qualtan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Qualtan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Qualtan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Qualtan side effects
See also:
What are the possible side effects of Qualtan?
The following adverse reaction is described elsewhere in labeling:
Renal dysfunction upon use with ramipril
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Hypertension
Qualtan has been evaluated for safety in more than 3700 patients, including 1900 treated for over 6 months and more than 1300 for over one year. Adverse experiences have generally been mild and transient in nature and have infrequently required discontinuation of therapy.
In placebo-controlled trials involving 1041 patients treated with various doses of Qualtan (20 to 160 mg) monotherapy for up to 12 weeks, the overall incidence of adverse events was similar to that in patients treated with placebo.
Adverse events occurring at an incidence of ≥1% in patients treated with Qualtan and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in Table 1.
Table 1 Adverse Events Occurring at an Incidence of ≥1% in Patients Treated with Qualtan and at a Greater Rate Than Patients Treated with Placebo
| Qualtan n=1455 % | Placebo n=380 % | |
| Upper respiratory tract infection | 7 | 6 |
| Back pain | 3 | 1 |
| Sinusitis | 3 | 2 |
| Diarrhea | 3 | 2 |
| Pharyngitis | 1 | 0 |
In addition to the adverse events in the table, the following events occurred at a rate of ≥1% but were at least as frequent in the placebo group: influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, coughing, hypertension, chest pain, nausea, and peripheral edema. Discontinuation of therapy because of adverse events was required in 2.8% of 1455 patients treated with Qualtan tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials.
The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients.
The incidence of cough occurring with Qualtan in 6 placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%).
In addition to those listed above, adverse events that occurred in more than 0.3% of 3500 patients treated with Qualtan monotherapy in controlled or open trials are listed below. It cannot be determined whether these events were causally related to Qualtan tablets:
Autonomic Nervous System: impotence, increased sweating, flushing; Body as a Whole: allergy, fever, leg pain, malaise; Cardiovascular: palpitation, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECG; CNS: insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesia; Gastrointestinal: flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, non-specific gastrointestinal disorders; Metabolic: gout, hypercholesterolemia, diabetes mellitus; Musculoskeletal: arthritis, arthralgia, leg cramps; Psychiatric: anxiety, depression, nervousness; Resistance Mechanism: infection, fungal infection, abscess, otitis media; Respiratory: asthma, bronchitis, rhinitis, dyspnea, epistaxis; Skin: dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Vascular: cerebrovascular disorder; and Special Senses: abnormal vision, conjunctivitis, tinnitus, earache.
During initial clinical studies, a single case of angioedema was reported (among a total of 3781 patients treated).
Clinical Laboratory Findings
In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of Qualtan tablets.
Hemoglobin: A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% Qualtan patients compared with 0.3% placebo patients. No patients discontinued therapy because of anemia.
Creatinine: A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% Qualtan patients compared with 0.3% placebo patients. One Qualtan-treated patient discontinued therapy because of increases in creatinine and blood urea nitrogen.
Liver Enzymes: Occasional elevations of liver chemistries occurred in patients treated with Qualtan; all marked elevations occurred at a higher frequency with placebo. No Qualtan-treated patients discontinued therapy because of abnormal hepatic function.
Cardiovascular Risk Reduction
Because common adverse reactions were well characterized in studies of Qualtan in hypertension, only adverse events leading to discontinuation and serious adverse events were recorded in subsequent studies of Qualtan for cardiovascular risk reduction. In TRANSCEND (N=5926, 4 years and 8 months of follow-up), discontinuations for adverse events were 8.4% on Qualtan and 7.6% on placebo. The only serious adverse events at least 1% more common on Qualtan than placebo were intermittent claudication (7% vs 6%) and skin ulcer (3% vs 2%).
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Qualtan. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Qualtan.
The most frequent spontaneously reported events include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), hypoglycemia (in diabetic patients), and angioedema (with fatal outcome).
Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers, including Qualtan.
Qualtan contraindications
See also:
What is the most important information I should know about Qualtan?
Hypersensitivity to Qualtan or to any of the excipients of Qualtan.
Biliary obstructive disorders and severe hepatic impairment.
The concomitant use with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).
In case of rare hereditary conditions that may be incompatible with an excipient of Qualtan, the use of Qualtan is contraindicated.
Use in pregnancy: The use of angiotensin II receptor antagonists is not recommended during the 1st trimester of pregnancy and should not be initiated during pregnancy.
Nonclinical studies with Qualtan do not indicate teratogenic effect, but have shown fetotoxicity.
Angiotensin II receptor antagonist exposure during the 2nd and 3rd trimester is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia).
Unless continued and angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonist should be stopped immediately and if appropriate, alternative therapy should be started.
Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Infants whose mothers have taken angiotensin II receptor antagonist should be closely observed for hypotension.
Use in lactation: Qualtan is contraindicated during lactation since it is not known whether it is excreted in human milk.
Animal studies have shown excretion of Qualtan in breast milk.
Active ingredient matches for Qualtan:
Telmisartan in Turkey.
List of Qualtan substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Qu Ya (China) | |
| RELMISART | |
| RELMISART 40MG TABLET 1 strip / 10 tablets each (La Renon Healthcare Pvt Ltd) | $ 0.72 |
| RELMISART 80MG TABLET 1 strip / 10 tablets each (La Renon Healthcare Pvt Ltd) | $ 1.20 |
| Relmisart 80mg Tablet (La Renon Healthcare Pvt Ltd) | $ 0.12 |
| ROZTEL (India) | |
| 40 mg x 10's (Rouzel) | |
| 80 mg x 10's (Rouzel) | |
| Roztel 40mg TAB / 10 (Rouzel) | |
| Roztel 80mg TAB / 10 (Rouzel) | |
| ROZTEL tab 40 mg x 10's (Rouzel) | |
| ROZTEL tab 80 mg x 10's (Rouzel) | |
| Roztel 40mg TAB / 10 (Rouzel) | |
| Roztel 80mg TAB / 10 (Rouzel) | |
| RPTEL 40MG TABLET | |
| RPTEL 40MG TABLET 1 strip / 10 tablets each (RPG Life Sciences Ltd) | $ 1.09 |
| Rulle (Mexico) | |
| SAFETELMI (Georgia) | |
| 20 mg x 10's (MSN Laboratories Ltd) | $ 0.41 |
| 40 mg x 10's (MSN Laboratories Ltd) | $ 0.78 |
| Safetelmi 20 mg Tablet (MSN Laboratories Ltd) | $ 0.04 |
| Safetelmi 40 mg Tablet (MSN Laboratories Ltd) | $ 0.08 |
| Safetelmi 20mg TAB / 10 (MSN Laboratories Ltd) | $ 0.41 |
| Safetelmi 40mg TAB / 10 (MSN Laboratories Ltd) | $ 0.78 |
| SAFETELMI 20 MG TABLET 1 strip / 10 tablets each (MSN Laboratories Ltd) | $ 0.43 |
| SAFETELMI 40 MG TABLET 1 strip / 10 tablets each (MSN Laboratories Ltd) | $ 0.77 |
| SAFETELMI 80 MG TABLET 1 strip / 10 tablets each (MSN Laboratories Ltd) | $ 1.09 |
| SAFETELMI tab 20 mg x 10's (MSN Laboratories Ltd) | $ 0.41 |
| SAFETELMI tab 40 mg x 10's (MSN Laboratories Ltd) | $ 0.78 |
| Safetelmi 20mg TAB / 10 (MSN Laboratories Ltd) | $ 0.41 |
| Safetelmi 40mg TAB / 10 (MSN Laboratories Ltd) | $ 0.78 |
| Safetelmi 20mg Tablet (MSN Laboratories Ltd) | $ 0.04 |
| Safetelmi 40mg Tablet (MSN Laboratories Ltd) | $ 0.08 |
| Safetelmi 80mg Tablet (MSN Laboratories Ltd) | $ 0.12 |
| Sai Ka (China) | |
| Saitan (China) | |
| Samertan (Chile) | |
| Sandoz Telmisartan (Canada) | |
| Sandoz Telmisartan tablet 80 mg (Sandoz Canada Incorporated (Canada)) | |
| Sandoz Telmisartan tablet 40 mg (Sandoz Canada Incorporated (Canada)) | |
| SARTEL (India) | |
| 20 mg x 10's (Intas Pharmaceuticals Ltd.) | |
| 40 mg x 10's (Intas Pharmaceuticals Ltd.) | $ 0.86 |
| 80 mg x 10's (Intas Pharmaceuticals Ltd.) | $ 1.35 |
| Sartel 20 mg Tablet (Intas Pharmaceuticals Ltd.) | $ 0.04 |
| Sartel 40 mg Tablet (Intas Pharmaceuticals Ltd.) | $ 0.10 |
| Sartel 80 mg Tablet (Intas Pharmaceuticals Ltd.) | $ 0.13 |
| Sartel 20mg TAB / 10 (Intas Pharmaceuticals Ltd.) | |
See 1793 substitutes for Qualtan | |
References
- DailyMed. "AMLODIPINE BESYLATE; TELMISARTAN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "Telmisartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Telmisartan". http://www.drugbank.ca/drugs/DB00966 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Qualtan are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Qualtan. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
